Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor - PubMed (original) (raw)
. 1991 Jan 15;266(2):740-6.
Affiliations
- PMID: 1898735
Free article
Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor
A Leyte et al. J Biol Chem. 1991.
Free article
Abstract
The acidic region of the Factor VIII light chain was studied with regard to structural requirements for the formation of a functional von Willebrand factor (vWF)-binding site. Factor VIII mutants lacking the B domain, with additional deletions and an amino acid replacement within the sequence 1649-1689 were constructed using site-directed mutagenesis and expressed in Cos-1 cells. These mutants, which were recovered as single-chain molecules with similar specific activities, were compared in their binding to immobilized vWF. Deletion of amino acids 741-1648 or 741-1668 did not affect the binding of Factor VIII to vWF. However, a mutant with a deletion of residues 741-1689 was no longer capable of interacting with vWF. This indicates a role for residues within the sequence 1669-1689 in the formation of a vWF-binding site. When recombinant Factor VIII was expressed in the presence of chlorate, an inhibitor of protein sulfation, the resulting Factor VIII displayed strongly reduced binding to vWF. vWF binding was completely abolished when within the sequence 1669-1689 the tyrosine residue Tyr1680, which is part of a consensus tyrosine sulfation sequence, was replaced by phenylalanine. The Factor VIII sequence 1673-1689 was identified as a high affinity substrate for tyrosylprotein sulfotransferase (Km = 57 microM) in cell-free sulfation studies. It is concluded that sulfation of Tyr1680 is required for the interaction of Factor VIII with vWF. Two synthetic peptides that represent the sequence 1673-1689, but differ with respect to sulfation of Tyr1680 are shown to have vWF binding affinity that is considerably lower than the Factor VIII protein. Several models to accommodate our findings are discussed.
Similar articles
- Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage.
Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Michnick DA, et al. J Biol Chem. 1994 Aug 5;269(31):20095-102. J Biol Chem. 1994. PMID: 8051097 - The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.
Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. Wise RJ, et al. J Biol Chem. 1991 Nov 15;266(32):21948-55. J Biol Chem. 1991. PMID: 1939217 - The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.
Leyte A, Voorberg J, Van Schijndel HB, Duim B, Pannekoek H, Van Mourik JA. Leyte A, et al. Biochem J. 1991 Feb 15;274 ( Pt 1)(Pt 1):257-61. doi: 10.1042/bj2740257. Biochem J. 1991. PMID: 1900418 Free PMC article. - To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB, van Velzen AS, Peyron I, Ten Brinke A, Fijnvandraat K, Voorberg J. Hartholt RB, et al. Blood Rev. 2017 Sep;31(5):339-347. doi: 10.1016/j.blre.2017.07.001. Epub 2017 Jul 4. Blood Rev. 2017. PMID: 28716211 Review. - Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.
Wise RJ, Ewenstein BM, Gorlin J, Narins SC, Jesson M, Handin RI. Wise RJ, et al. Hum Genet. 1993 May;91(4):367-72. doi: 10.1007/BF00217358. Hum Genet. 1993. PMID: 8500791 Review.
Cited by
- Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain.
Childers KC, Cowper B, Vaughan JD, McGill JR, Davulcu O, Lollar P, Doering CB, Coxon CH, Spiegel PC Jr. Childers KC, et al. J Thromb Haemost. 2024 Sep;22(9):2449-2459. doi: 10.1016/j.jtha.2024.05.024. Epub 2024 Jun 5. J Thromb Haemost. 2024. PMID: 38849084 - Custom Workflow for the Confident Identification of Sulfotyrosine-Containing Peptides and Their Discrimination from Phosphopeptides.
Daly LA, Byrne DP, Perkins S, Brownridge PJ, McDonnell E, Jones AR, Eyers PA, Eyers CE. Daly LA, et al. J Proteome Res. 2023 Dec 1;22(12):3754-3772. doi: 10.1021/acs.jproteome.3c00425. Epub 2023 Nov 8. J Proteome Res. 2023. PMID: 37939282 Free PMC article. - Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases.
Xu P, Cai X, Guan X, Xie W. Xu P, et al. Pharmacol Ther. 2023 Nov;251:108540. doi: 10.1016/j.pharmthera.2023.108540. Epub 2023 Sep 28. Pharmacol Ther. 2023. PMID: 37777160 Free PMC article. Review. - Considerations for defining +80 Da mass shifts in mass spectrometry-based proteomics: phosphorylation and beyond.
Daly LA, Clarke CJ, Po A, Oswald SO, Eyers CE. Daly LA, et al. Chem Commun (Camb). 2023 Sep 26;59(77):11484-11499. doi: 10.1039/d3cc02909c. Chem Commun (Camb). 2023. PMID: 37681662 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous